Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Med.

Sec. Nephrology

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1626324

This article is part of the Research TopicIntegrative Omics for Insights into Human Disease Mechanisms and Therapeutic PotentialsView all articles

Biomarker research for Henoch-Schönlein purpura nephritis based on "omics" techniques

Provisionally accepted
Xuejiao ZhouXuejiao Zhou1,2Zhengwei YuanZhengwei Yuan3Hongkun JiangHongkun Jiang1Yaoyao JuYaoyao Ju1Cheng ChenCheng Chen1Wenjie ZhangWenjie Zhang1Huining LiuHuining Liu1Liqing ZhangLiqing Zhang2Meixia QiMeixia Qi2Dong AnDong An1*
  • 1The First Affiliated Hospital of China Medical University, Shenyang, China
  • 2The Fifth People’s Hospital of Datong, Datong, China
  • 3Key Laboratory of Health Ministry for Congenital Malformation, Shenyang, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Henoch-Schönlein purpura (HSP) is a common autoimmune disease in children. The lesions primarily involve small vessels in the skin, kidneys, joints and intestines. Henoch-Schönlein purpura nephritis (HSPN) caused by HSP is the main factor affecting the prognosis and outcome of the disease, and severe cases may develop into end-stage renal insufficiency. Renal biopsy serves as the primary diagnostic tool for HSPN, but it is an invasive test with poor reproducibility. which is not conducive to clinical promotion. The discovery of new biomarkers using traditional laboratory testing methods and omics techniques provide new possibilities for HSPN to discover additional biomarkers, such as genomics, transcriptomics, proteomics, metabolomics and epigenomics. These technologies offer benefits such as high throughput, high sensitivity, and reduced need for biological fluid samples, which are expected to make greater contributions to the screening of promising biomarkers for purpuric nephritis. The current article reviews recent advances in omics-based research on potential biomarkers in samples from different sources of HSPN, including blood, urine, kidney tissue, and associated cells, which may provide a foundation for early diagnosis, prognosis, and treatment of HSPN.

Keywords: Henoch-Schönlein Purpura nephritis, immunoglobulin A vasculitis, biomarker, omics, Henoch-Schönlein purpura

Received: 10 May 2025; Accepted: 27 Aug 2025.

Copyright: © 2025 Zhou, Yuan, Jiang, Ju, Chen, Zhang, Liu, Zhang, Qi and An. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dong An, The First Affiliated Hospital of China Medical University, Shenyang, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material